MARKET

VTVT

VTVT

Vtv Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4214
-0.0186
-4.23%
Pre Market: 0.4380 +0.0166 +3.94% 09:20 05/19 EDT
OPEN
0.4268
PREV CLOSE
0.4400
HIGH
0.4350
LOW
0.4100
VOLUME
11
TURNOVER
0
52 WEEK HIGH
2.880
52 WEEK LOW
0.3821
MARKET CAP
37.94M
P/E (TTM)
-1.7669
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Benzinga · 1d ago
vTv Therapeutics GAAP EPS of -$0.10, revenue of $2M
vTv Therapeutics press release (NASDAQ:VTVT): Q1 GAAP EPS of -$0.10. Revenue of $2M (+100.0% Y/Y). The Company’s cash position as of March 31, 2022, was $12.1 million compared to $13.4
Seekingalpha · 05/12 12:27
vTv Therapeutics: Q1 Earnings Insights
  vTv Therapeutics (NASDAQ:VTVT) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:45 AM. Here's what investors need to know about the announcement.
Benzinga · 05/12 12:25
BRIEF-VTV Therapeutics Inc - QTRLY Net Loss Per Share Of $0.10
reuters.com · 05/12 10:17
vTv Therapeutics (NASDAQ:VTVT) investors are sitting on a loss of 89% if they invested five years ago
Some stocks are best avoided. It hits us in the gut when we see fellow investors suffer a loss. Spare a thought for...
Simply Wall St. · 03/31 23:34
vTv Therapeutics's Return On Capital Employed Overview
vTv Therapeutics (NASDAQ:VTVT) brought in sales totaling $9.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 547.3%, resulting in a loss of $9.48 million.
Benzinga · 03/31 13:50
vTv Therapeutics GAAP EPS of -$0.11
vTv Therapeutics press release (NASDAQ:VTVT): Q4 GAAP EPS of -$0.11. Revenue of $9K The Company's cash position as of December 31, 2021, was $13.4M compared to $19.6M as of September
Seekingalpha · 03/30 04:44
BRIEF-vTv Therapeutics Says Company’S Cash Position As Of December 31, 2021, Was $13.4 Million
reuters.com · 03/29 21:33
More
No Data
Learn about the latest financial forecast of VTVT. Analyze the recent business situations of Vtv Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VTVT stock price target is 3.750 with a high estimate of 6.00 and a low estimate of 1.500.
High6.00
Average3.750
Low1.500
Current 0.4750
EPS
Actual
Estimate
-0.09-0.07-0.04-0.02
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 45
Institutional Holdings: 6.95M
% Owned: 7.72%
Shares Outstanding: 90.04M
TypeInstitutionsShares
Increased
7
214.58K
New
9
3.48M
Decreased
9
50.92K
Sold Out
10
312.51K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.00%
Pharmaceuticals & Medical Research
+0.51%
Key Executives
Director
Robin Abrams
Director
Hersh Kozlov
Director
Richard Nelson
Independent Director
John Fry
Independent Director
Noel Spiegel
Independent Director
Howard Weiner
No Data
No Data
About VTVT
vTv Therapeutics Inc. is a clinical-stage pharmaceutical company that is engaged in the discovery and development of orally administered small molecule drug candidates. It is developing a program for the treatment of type I diabetes TTP399 and for psoriasis HPP737. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. The Company is also conducting a multiple ascending dose Phase I study of HPP737, an orally administered phosphodiesterase type IV inhibitor, to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of HPP737 in healthy volunteers as part of its psoriasis program. Its TTP273 is an oral, small molecule, glucagon-like peptide I (GLP-1) receptor agonist being evaluated for the treatment of type II diabetes mellitus.

Webull offers kinds of vTv Therapeutics Inc stock information, including NASDAQ:VTVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTVT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VTVT stock methods without spending real money on the virtual paper trading platform.